DelveInsight’s, “ Diabetic Macular Edema -Pipeline Insights, 2017â€, report provides comprehensive insights about pipeline drugs across this Diabetic Macular Edema. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Diabetic Macular Edema. This report provides information on the therapeutic development for Diabetic Macular Edema, dealing with all the pipeline drugs and comparative analysis at various stages covering all clinical, pre-clinical as well as discovery products. The report further contains details on dormant products and discontinued products. Therapeutic assessment of all the active products by route of administration and molecule type is also covered in this report.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Table 1:Total Products for Diabetic Macular Edema
Table 2: Products in Clinical Stage
Table 3: Products in Pre-Clinical and Discovery Stage
Table 4: Assessment by Route of Administration
Table 5: Assessment by Stage and Route of Administration
Table 6: Assessment by Molecule Type
Table 7: Assessment by Stage and Molecule Type
Table 8: Inactive Products
Figure 1:Total Products for Diabetic Macular Edema
Figure 2: Products in Clinical Stage
Figure 3: Products in Pre-Clinical and Discovery Stage
Figure 4: Assessment by Route of Administration
Figure 5: Assessment by Stage and Route of Administration
Figure 6: Assessment by Molecule Type
Figure 7: Assessment by Stage and Molecule Type
Figure 8: Inactive Products
